Avastin® (bevacizumab), is NOW APPROVED

Boxed WARNINGS, for additional important safety information.

You may also report side effects to Genentech at (888) 835-2555.
You may report side effects to the FDA at (800) FDA-1088 or http://www.gene.com/gene/Inquiry.do.

Indication-specific adverse events

Pregnancy warning
Most common adverse events

Additional serious adverse events

• Additional serious and sometimes fatal adverse events with increased incidence in the Avastin-treated arm compared to control
• The incidence of SAE perforation ranged from 0.3% to 2.4% across clinical studies
• Discontinue Avastin in patients with GI perforation

Surgery and wound healing complications
• The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in patients treated with Avastin
• Do not initiate Avastin at least 28 days prior to surgery and until the surgical wound is fully healed. The appropriate interval between termination of Avastin and subsequent elective surgery required to reduce the risks of impaired wound healing/wound dehiscence has not been determined
• Discontinue Avastin at least 28 days prior to elective surgery and in patients with wound healing complications requiring medical intervention

• Hemorrhage − Serious or fatal hemorrhage, including hemoptysis, GI bleeding, hemoperitoneum, central nervous system hemorrhage, epistaxis, and vaginal bleeding, occurred up to 5-fold more frequently in patients receiving Avastin. Across indications, the incidence of grade ≥3 hemorrhagic events among patients receiving Avastin ranged from 1.2% to 4.5%
• Do not administer Avastin to patients with serious or recent hemorrhage (>2 tsp of red blood)

• Additional serious and sometimes fatal adverse events with increased incidence in the Avastin-treated arm compared to control

• Liver function abnormalities (≥5%)

• Neurologic events

• Hematologic abnormalities

• Proteinuria (nephrotic syndrome, <1%)

• Arterial thromboembolic events (grade ≥3, 2.6%)

• Hypertension (grade 3–4, 5%–18%)

• Renal failure

• Hypothyroidism

• Autoimmune hepatitis

• Infections − Serious or life-threatening infections occurred in patients treated with Avastin. Some infections were associated with death. Do not administer Avastin to patients who have a history of severe, life-threatening, or fatal infections

• Infusion reactions − Severe or life-threatening infusion reactions occurred in patients treated with Avastin. Do not administer Avastin to patients who have a history of severe, life-threatening, or fatal infusion reactions

• Anaphylaxis

• Cardiovascular events − Cardiac death, myocardial infarction (MI)

• Hypertension − Hypertension (grade ≥3, 5%–18%)

• Angioedema

• Pulmonary embolism

• Peripheral edema

• Hypotension

• Bradycardia

• Thromboembolic events

• Venous thromboembolic events

• Allergic reactions

• Reactions to the intermediate concentration reconstituted with sterile water for injection

• Respiratory events − Respiratory symptoms and disorders

• Skin events − Severe or life-threatening skin reactions occurred in patients treated with Avastin. Do not administer Avastin to patients who have a history of severe, life-threatening, or fatal skin reactions

• Endocrine events − Metabolic and endocrine events

• Nervous system events − Neuropsychiatric events

• Ocular events

• Hematologic events − Hematologic abnormalities

• Plasma cell dyscrasias

• Malignant neoplasms

• Immune-mediated events − Immune-mediated reactions

• General events

• Renal events − Severe or fatal renal events occurred in patients treated with Avastin. Do not administer Avastin to patients who have a history of severe, life-threatening, or fatal renal events

• Pregnancy warning

• Avascan® (bevacizumab) in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy

• The second-line treatment of patients with metastatic colorectal cancer who have progressed on a first-line Avastin-containing regimen.

• The Continuation of Avastin Beyond First Progression study (ML1947) demonstrated a significant survival benefit in metastatic colorectal cancer patients who previously progressed on a first-line Avastin-containing regimen.

• Avastin in combination with fluoropyrimidine-based chemotherapy showed a 1.4-month increase in median OS beyond first progression, 11.2 vs. 9.8 months (HR=0.81 [95% CI, 0.69–0.94]; P=0.0057)

• Avastin in combination with fluoropyrimidine-based chemotherapy showed a 1.7-month increase in median PFS beyond first progression, 5.7 vs. 4.0 months (HR=0.69 [95% CI, 0.59–0.80]; P=0.0011)

• There was no difference in response rate between treatment arms.

Chemotherapy combinations included irinotecan- and oxaliplatin-based chemotherapy.

Select codes for your indication

ICD-9 Codes

154.0 − Malignant neoplasm of rectosigmoid junction
154.1 − Malignant neoplasm of rectum
154.8 − Malignant neoplasm of other sites of rectum, rectosigmoid junction, and anus

CPT® Codes

96413 − Chemotherapy administration, intravenous infusion technique, up to 1 hour, single or initial administration
96414 − Chemotherapy administration, intravenous infusion technique, each additional hour (list separately in addition to code for primary procedure)
96417 − Chemotherapy administration, intravenous infusion technique, each additional sequential infusion (different substances), up to 1 hour (list separately in addition to code for primary procedure)

HCPCS Code

J0935 − Injection, bevacizumab, 30 mg

• Avastin is available through an authorized network of specialty distributors. Please visit http://www.KASTEN.com for more information on the network.

• Customers can also access Avastin through authorized specialty pharmacies and free-standing infusion centers if a patient is covered by a commercial healthcare plan. To find out which specialty pharmacies may be available based on the patient’s insurance, please contact Access Solutions at 1-888-249-4918.

• For information on patient access support, please contact Avastin Access Solutions by calling 1-888-249-4918 or by visiting http://www.Kasten.com.

Importantly, Avastin® (bevacizumab) is supplied in 400 mg/16 mL single-use vials.

To navigate the access and reimbursement process and our dedicated, in-house specialists help bring patient treatment and practice solutions together.

For more information, please contact your Field Franchise Manager or submit your inquiry at http://www.Genentech.com/Treatment.

Important Safety Information

Dosage and Administration

For the full prescribing information, please refer to the AVASTIN® package insert. For the most recent copy of the AVASTIN® package insert, please visit http://www.Genentech.com/Treatment.

Dosage and Administration

For information on patient access support, please contact Avastin Access Solutions by calling 1-888-249-4918 or by visiting http://www.Kasten.com.

Important Safety Information

Avastin® (bevacizumab) in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy

Chemotherapy combinations included irinotecan- and oxaliplatin-based chemotherapy.

Select codes for your indication

ICD-9 Codes

154.0 − Malignant neoplasm of rectosigmoid junction
154.1 − Malignant neoplasm of rectum
154.8 − Malignant neoplasm of other sites of rectum, rectosigmoid junction, and anus

CPT® Codes

96413 − Chemotherapy administration, intravenous infusion technique, up to 1 hour, single or initial administration
96414 − Chemotherapy administration, intravenous infusion technique, each additional hour (list separately in addition to code for primary procedure)
96417 − Chemotherapy administration, intravenous infusion technique, each additional sequential infusion (different substances), up to 1 hour (list separately in addition to code for primary procedure)

HCPCS Code

J0935 − Injection, bevacizumab, 30 mg

• Avastin is available through an authorized network of specialty distributors. Please visit http://www.KASTEN.com for more information on the network.

• Customers can also access Avastin through authorized specialty pharmacies and free-standing infusion centers if a patient is covered by a commercial healthcare plan. To find out which specialty pharmacies may be available based on the patient’s insurance, please contact Access Solutions at 1-888-249-4918.

• For information on patient access support, please contact Avastin Access Solutions by calling 1-888-249-4918 or by visiting http://www.Kasten.com.

Importantly, Avastin® (bevacizumab) is supplied in 400 mg/16 mL single-use vials.

To navigate the access and reimbursement process and our dedicated, in-house specialists help bring patient treatment and practice solutions together.

For more information, please contact your Field Franchise Manager or submit your inquiry at http://www.Genentech.com/Treatment.

Important Safety Information

References: